Literature DB >> 19330060

Section III: Treatment of Advanced Gastrointestinal Cancers.

Howard S Hochster, Eileen M O'Reilly, Jaffer A Ajani, Alan P Venook.   

Abstract

Entities:  

Year:  2007        PMID： 19330060      PMCID： PMC2659794     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  15 in total

1.  Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.

Authors:  Axel Grothey; Daniel Sargent
Journal:  J Clin Oncol       Date:  2005-12-20       Impact factor: 44.544

2.  Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.

Authors:  W Y Lau; T W Leung; S K Ho; M Chan; D Machin; J Lau; A T Chan; W Yeo; T S Mok; S C Yu; N W Leung; P J Johnson
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

3.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

4.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

5.  Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.

Authors:  Kazuhiro Yoshida; Motoki Ninomiya; Norihisa Takakura; Naoki Hirabayashi; Wataru Takiyama; Yuji Sato; Satoru Todo; Masanori Terashima; Mitsukazu Gotoh; Jyunnichi Sakamoto; Masahiko Nishiyama
Journal:  Clin Cancer Res       Date:  2006-06-01       Impact factor: 12.531

6.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Authors:  E Van Cutsem; H van de Velde; P Karasek; H Oettle; W L Vervenne; A Szawlowski; P Schoffski; S Post; C Verslype; H Neumann; H Safran; Y Humblet; J Perez Ruixo; Y Ma; D Von Hoff
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

7.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

8.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

9.  Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study.

Authors:  V Heinemann; R Labianca; A Hinke; C Louvet
Journal:  Ann Oncol       Date:  2007-07-28       Impact factor: 32.976

10.  A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.

Authors:  S R Bramhall; J Schulz; J Nemunaitis; P D Brown; M Baillet; J A C Buckels
Journal:  Br J Cancer       Date:  2002-07-15       Impact factor: 7.640
View more
  1 in total

Review 1.  A 10-year review of survival among patients with metastatic gastrointestinal cancers: a population-based study.

Authors:  Omar Abdel-Rahman
Journal:  Int J Colorectal Dis       Date:  2020-03-17       Impact factor: 2.571
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.